Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.
Press Enter ↵ to search evidence
Explore by Goal
"An expert is a person who has made all the mistakes that can be made in a very narrow field."
- Niels Bohr
Quick Analysis Plan
Copied
A rigorous plan centers on quantifying the OMV@PDA self-reinforcing loop: neutrophil-selective uptake (83.2%), photothermally triggered second accumulation peak (~1.6-fold at 10 h), neutrophil colocalization (54.1% vs 24.7%), and 95% tumor inhibition, all reported in an orthotopic 4T1 mouse study of n=5 groups
Long Analysis Plan
Computational Plan for the OMV@PDA Self-Reinforcing Delivery Loop
Goal: Model, test, and visualize the two-phase accumulation hypothesis — passive EPR peak (~2 h) followed by a photothermally amplified neutrophil-mediated peak (~10 h) — using only quantitative data reported in the 4T1/BALB-c study (n=5 per group) .
Analysis modules (Python3):
Module 1 — Biodistribution kinetics: fit the reported PA/ICP-MS time course (2 h vs 10 h vs 24 h) to a two-compartment accumulation model (scipy.optimize.curve_fit) distinguishing EPR-driven influx from PTT-triggered neutrophil-mediated influx; test whether the 10 h/2 h ratio (~1.6) and 24 h sustainment are statistically separable from PDA-only controls.
Module 2 — Neutrophil-targeting quantification: compare 83.2% OMV@PDA uptake vs 1.35-fold PDA baseline; compute effect size and required power for follow-up flow cytometry replicates (statsmodels).
Module 3 — Colocalization causality: 54.1% (OMV@PDA+PTT) vs 24.7% (PDA+PTT) neutrophil colocalization; use contingency testing (Fisher exact) and Monte-Carlo CI bootstrapping (n=5 group size demands uncertainty quantification).
Module 4 — Formulation-design optimizer: regress OMV:PDA coating ratio (1:5 optimum) against uptake %, zeta potential (-12.95 vs -18.75 mV), and diameter (106.5 vs 100.8 nm) to predict coating-ratio optima (sklearn Gaussian process regression).
Module 5 — Photothermal model: solve the heat-diffusion ODE for 808 nm, 0.5 W/cm² exposure (45 °C at 110 s; 66 °C at 540 s; 5 stable ON/OFF cycles) to identify minimal safe PTT doses that still exceed the chemotaxis-induction threshold.
Module 6 — Immune-response network: build a directed graph (networkx) linking PTT → inflammation → chemokines (IL-8, IL-1β) → neutrophil recruitment → DC maturation (CD11c+CD80+) → CD8+ T cell infiltration (2.47-fold) → tumor inhibition (95%).
Key blindspots to encode explicitly: single tumor model (4T1), n=5 groups, mouse-to-human translation untested, OMV immunogenicity risk, and data available only on request — flag all as structured metadata fields in the analysis pipeline so any re-analysis inherits these caveats .
Falsification hooks to automate: (a) neutrophil-depletion should abrogate the 10 h peak; (b) PTT-blocking should collapse colocalization to PDA-baseline; (c) reproducibility across other tumor models. Encode these as unit tests in a snakemake workflow so any new dataset is automatically checked against the loop hypothesis.
simulated=True; assumptions: two-compartment accumulation, PA signal proportional to tumor nanoparticle mass, reported 2 h and 10 h means with ±15% uncertainty; data sourced from OMV@PDA study Figure 4
Generated scientific data; not direct experimental measurements.
Analysis Wizard
Fitting a two-compartment kinetic model to reported tumor accumulation data and bootstrapping confidence intervals to test whether the PTT-amplified second peak is statistically separable from EPR baseline.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
OMV coating acts merely as a passive size/charge modifier rather than a PAMP-driven targeting ligand — rejected because the 54.1% vs 24.7% colocalization gap and 1.35-fold uptake differential persist beyond what diameter/zeta changes alone would predict.